A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Lenalidomide in Combination With Sunitinib in Subjects With Advanced or Metastatic Renal Cell Carcinoma
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase 1: Maximum Tolerated Dose (MTD)
Within 21 days of treatment induction
No
Abderrahim Fandi, MD
Study Director
Celgene Corporation
United States: Food and Drug Administration
CC-5013-RCC-001
NCT00975806
September 2009
October 2011
Name | Location |
---|---|
University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan 48109-0752 |
Tennessee Oncology | Nashville, Tennessee 37203 |
Cleveland Clinic Main Campus | Cleveland, Ohio 44195 |